Unknown

Dataset Information

0

Is pretreatment Epstein-Barr virus DNA still associated with 6-year survival outcomes in locoregionally advanced nasopharyngeal carcinoma?


ABSTRACT: Purpose: The objective of this study was to confirm the association between pretreatment Epstein-Barr virus (EBV) DNA (pre-DNA) load and survival outcomes after long-term follow-up in patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC). Materials and Methods: Between November 2009 and February 2012, a total of 1036 patients with LA-NPC were enrolled. There were 762 patients in stage III and 274 in stage IVA-B. All patients were treated with radical radiotherapy with or without chemotherapy, and pre-DNA concentrations were quantified by a polymerase chain reaction assay. Patient outcomes were evaluated. Results: The 5-year overall survival (OS), distant metastasis-free surviva (DMFS), locoregional relapse-free survival (LRFS), and progression-free survival (PFS) rates were 84.7%, 87.0%, 90.2%, and 77.1%, respectively. By using previously defined pre-DNA cutoff value (1500 copies/ml pretreatment), pre-DNA was an independent prognostic predictor for OS, DMFS, and PFS using log-rank test. Multivariate Cox analysis also confirmed these results. Subgroup analysis indicated that the 5-year OS, DMFS, and PFS rates in patients staged IVA-B with pre-DNA < 1500 copies/ml were similar to those patients staged III with pre-DNA ? 1500 copies/ml, whereas patients staged IVA-B patients with pre-DNA ? 1500 copies/ml predicted worse outcome. Conclusions: In this expanded study, the prognostic significance of pre-DNA was confirmed using predefined cutoff value in an independent patient group, and pre-DNA was identified as an independent prognostic marker for the risk stratification in LA-NPC.

SUBMITTER: Jin YN 

PROVIDER: S-EPMC5436249 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature

altmetric image

Publications

Is pretreatment Epstein-Barr virus DNA still associated with 6-year survival outcomes in locoregionally advanced nasopharyngeal carcinoma?

Jin Ya-Nan YN   Yao Ji-Jin JJ   Zhang Fan F   Wang Si-Yang SY   Zhang Wang-Jian WJ   Zhou Guan-Qun GQ   Qi Zhen-Yu ZY   Sun Ying Y  

Journal of Cancer 20170312 6


<b>Purpose:</b> The objective of this study was to confirm the association between pretreatment Epstein-Barr virus (EBV) DNA (pre-DNA) load and survival outcomes after long-term follow-up in patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC). <b>Materials and Methods:</b> Between November 2009 and February 2012, a total of 1036 patients with LA-NPC were enrolled. There were 762 patients in stage III and 274 in stage IVA-B. All patients were treated with radical radiotherapy  ...[more]

Similar Datasets

| S-EPMC8793774 | biostudies-literature
| S-EPMC8330545 | biostudies-literature
| S-EPMC10417187 | biostudies-literature
| S-EPMC5543490 | biostudies-literature
| S-EPMC5029695 | biostudies-literature
| S-EPMC8551638 | biostudies-literature
| S-EPMC5111216 | biostudies-literature
| S-EPMC7247807 | biostudies-literature
| S-EPMC6299978 | biostudies-literature
| S-EPMC6308091 | biostudies-literature